Will Rising Earnings Estimates and Upgraded Views Change Itron's (ITRI) Narrative?

• In recent days, analysts have revised their earnings estimates for Itron upward, contributing to an average brokerage recommendation of 1.92, between Strong Buy and Buy, and signaling improving sentiment around the company’s near-term prospects.
• This shift comes despite Itron’s earlier underperformance versus the broader market and concerns about its slower long-term revenue growth, weaker margins, and past capital efficiency challenges.
• With analyst earnings estimates moving higher, we’ll now examine how this renewed optimism could reshape Itron’s existing investment narrative.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Itron Investment Narrative Recap

To own Itron, you need to believe its smart metering and grid software footprint can translate into steadily improving earnings, even if revenue growth stays modest. The recent upward earnings revisions support that earnings side of the thesis in the near term, but they do little to resolve the bigger risk that utilities and regulators could still slow or defer large projects, which remains the key swing factor for results over the next year.

Against this backdrop, the US$152.25 million share repurchase program, including US$52.25 million spent in the latest quarter, is the most relevant recent announcement. It reinforces the idea that management sees value in the current share price, but it does not change the fact that Q2 2026 revenue and earnings declined year on year, so execution on the project backlog and regulatory approvals still matters far more to the story.

Yet behind this more upbeat earnings sentiment, there is still a risk investors should be aware of around how quickly utilities approve and execute...

Read the full narrative on Itron (it's free!)

Itron's narrative projects $2.7 billion revenue and $313.0 million earnings by 2029.

Uncover how Itron's forecasts yield a $126.70 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community value Itron between US$71.50 and US$126.70, reflecting a wide spread of expectations. When you set those views against the recent upward earnings revisions, it underlines how differently people assess the same risks and catalysts, and why it can help to compare several perspectives before deciding how Itron might fit into your portfolio.

Explore 4 other fair value estimates on Itron - why the stock might be worth 29% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Itron research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Itron research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Itron's overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 48 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com